Welcome to our dedicated page for Organovo Holding news (Ticker: ONVO), a resource for investors and traders seeking the latest updates and insights on Organovo Holding stock.
Organovo Holdings, Inc. (ONVO) is a leader in 3D bioprinting technology focused on creating functional human tissues for medical research and therapeutic development. This page serves as the definitive source for verified news and official announcements related to the company’s scientific advancements and business operations.
Investors and researchers will find timely updates on clinical research programs, strategic partnerships with pharmaceutical companies, and developments in Organovo’s proprietary 3D tissue platforms. The curated collection includes press releases about preclinical studies, technology licensing agreements, and financial performance updates.
All content is rigorously verified to ensure accuracy, with direct links to primary sources such as SEC filings and peer-reviewed publications. Regular updates provide insights into Organovo’s work in areas like inflammatory bowel disease research and tissue model validation.
Bookmark this page to stay informed about ONVO’s progress in bridging the gap between laboratory discoveries and real-world therapeutic applications through innovative 3D bioprinting solutions.
Organovo Holdings (Nasdaq: ONVO) announces that its lead clinical stage drug, FXR314, will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, scheduled for November 17, 2024, will be delivered by Dr. Eric Lawitz of the Texas Liver Institute and will discuss findings from the FXR314 Phase 2 MASH study. The presentation will cover pharmacokinetics, safety, and efficacy of this novel non-bile acid FXR agonist in patients with metabolic dysfunction-associated steatohepatitis.
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis trials. The company aims to demonstrate FXR314's activity matching results from predictive animal models and 3D human models of ulcerative colitis and Crohn's disease. Murphy emphasized the importance of swift trial completion for investors and patients, noting the strong M&A activity in IBD, referencing Lilly's $3.2B acquisition of Morphic following positive Phase 2a results. The presentation webcast is available for viewing on the Jones Trading website.
Organovo Holdings (Nasdaq: ONVO) presented promising data at Digestive Disease Week (DDW2024) in Washington, D.C., showcasing the potential of FXR314 for treating inflammatory bowel disease (IBD). The study highlights the benefits of combining FXR314, a non-steroidal, non-bile acid FXR agonist, with tofacitinib, a JAK inhibitor. Results showed improvements in intestinal barrier function, inflammation, and fibrosis in 3D and preclinical IBD models. Both compounds, when used at optimal and sub-efficacious concentrations, demonstrated enhanced therapeutic effects. FXR314 alone also showed similar efficacy to approved therapies. These findings support the potential of FXR314 for monotherapy and combination therapy in future clinical studies.
Organovo, a clinical-stage biotechnology company (Nasdaq: ONVO), announces its presentation at Digestive Diseases Week (DDW2024) in Washington, D.C., from May 18-21, 2024. The company will present data on its lead drug, FXR314, a combination therapy with tofacitinib for inflammatory bowel disease (IBD) and ulcerative colitis. The poster titled 'Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel disease' will be showcased on May 18, 2024, at 12:30 EDT. This event is a significant opportunity for Organovo to engage with prescribers and potential partners.
Organovo Holdings, Inc. announced the pricing of a public offering of 6,562,500 shares of common stock and common warrants, expecting gross proceeds of $5.25 million. The offering price per share is $0.80 with common warrants exercisable at the same price. The offering is set to close on May 13, 2024. JonesTrading Institutional Services is the placement agent for the offering.
FAQ
What is the current stock price of Organovo Holding (ONVO)?
What is the market cap of Organovo Holding (ONVO)?
